Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
12/2003
12/17/2003EP1371650A1 Activator for peroxisome proliferator-activated receptor
12/17/2003EP1371647A2 Pyridine-3-carboxylic acid derivatives and their use as intermediates
12/17/2003EP1371646A1 Aryl-substituted alicyclic compound and medical composition comprising the same
12/17/2003EP1371645A1 Process for the preparation of the 2'-(R)-Glycopyrronium Enantiomers and their use in medicaments
12/17/2003EP1371640A1 Novel a-lipoic acid derivative and use thereof
12/17/2003EP1371377A1 Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof
12/17/2003EP1371367A1 Use of naaladase inhibitors for the manufacture of a medicament for the treatment of certain diseases
12/17/2003EP1371361A1 Novel suppository form comprising an acid-labile active compound
12/17/2003EP1370676A2 Mouse cytokine receptor
12/17/2003EP1370673A1 Topoisomerase i selective cytotoxic sugar derivatives of indolopyrrolocarbazoles
12/17/2003EP1370670A2 Processes for enhanced production of pantothenate
12/17/2003EP1370662A2 Polypeptide sequences of drug metabolizing enzymes and polynucleotide sequences coding therefor
12/17/2003EP1370655A2 Secreted human proteins
12/17/2003EP1370641A2 Use of stem cells and cd6-depleted stem cells for inducing tolerance of allogenic transplants and/or for treating leukaemia
12/17/2003EP1370586A2 Nuclear hormone receptor ligand binding domain
12/17/2003EP1370584A2 Nuclear hormone receptor ligand binding domain
12/17/2003EP1370580A2 A new essential downstream component of the wingless signalling pathway
12/17/2003EP1370579A1 Matrix gene expression in chondrogenesis
12/17/2003EP1370575A2 Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
12/17/2003EP1370573A2 Low molecular serine protease inhibitors comprising polyhydroxy-alkyl and polyhydroxy-cycloalkyl radicals
12/17/2003EP1370572A2 Mitochondrial membrane permeabilization by hiv-1 vpr and methods of screening
12/17/2003EP1370569A1 Process for preparing n6-substituted aminopurine ribofuranose nucleosides
12/17/2003EP1370562A1 Thieno[2,3-d]pyrimidindione derivatives as matrix metalloproteinase inhibitors
12/17/2003EP1370561A2 Tetrahydro-pyrazino[1,2-a]indoles for the treatment of central nervous disorders
12/17/2003EP1370559A1 Triazolopyridines as anti-inflammatory agents
12/17/2003EP1370558A1 Piperazine- and piperidine-derivatives as melanocortin receptor agonists
12/17/2003EP1370557A1 Benzimidazole anti-inflammatory compounds
12/17/2003EP1370556A1 Metalloproteinase inhibitors
12/17/2003EP1370553A2 Rho-kinase inhibitors
12/17/2003EP1370552A2 Rho-kinase inhibitors
12/17/2003EP1370548A1 P-thienylbenzyl-amides serving as agonists of angiotensin-(1-7)-receptors, method for the production thereof, their use and pharmaceutical preparations containing the same
12/17/2003EP1370547A1 Benzoaxathiepin derivatives and their use as medicines
12/17/2003EP1370546A2 Novel amines as histamine-3 receptor ligands and their therapeutic applications
12/17/2003EP1370543A2 Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors
12/17/2003EP1370538A1 Metalloproteinase inhibitors
12/17/2003EP1370537A1 Metalloproteinase inhibitors
12/17/2003EP1370536A1 Metalloproteinase inhibitors
12/17/2003EP1370535A1 Metalloproteinase inhibitors
12/17/2003EP1370534A1 Metalloproteinase inhibitors
12/17/2003EP1370533A2 Imidiazole derivatives and their use as agonists selective at alpha 2b or 2b/2c adrenergic receptors
12/17/2003EP1370531A1 Phenylalanine enamide derivatives possessing a cyclobutene group, for use as integrin inhibitors
12/17/2003EP1370528A1 Mch antagonists and their use in the treatment of obesity
12/17/2003EP1370527A1 Indolone derivatives having vascular-damaging activity
12/17/2003EP1370526A1 Diamides which inhibit tryptase and factor xa activity
12/17/2003EP1370522A1 Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours
12/17/2003EP1370521A1 Formanilide derivatives as beta2-adrenoreceptor agonists
12/17/2003EP1370520A1 Aryl and biaryl compounds having mch modulatory activity
12/17/2003EP1370518A2 Tryptase-inhibitors
12/17/2003EP1370510A2 Hiv integrase inhibitors
12/17/2003EP1370298A1 Elongated and multiple spacers in activatible prodrugs
12/17/2003EP1370295A2 Neutral and anionic colloidal particles for gene delivery
12/17/2003EP1370293A2 Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists
12/17/2003EP1370280A2 Stabilized interleukin 2
12/17/2003EP1370277A1 Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis
12/17/2003EP1370276A2 Medical uses of intercellular communication facilitating compounds
12/17/2003EP1370275A2 Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting gm1-ganglioside
12/17/2003EP1370272A1 Inhibitors of extracellular proteases
12/17/2003EP1370268A2 Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
12/17/2003EP1370264A2 Nicotinic receptor agonists for the treatment of inflammatory diseases
12/17/2003EP1370261A2 New use
12/17/2003EP1370260A2 Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators
12/17/2003EP1370258A2 Peptide deformylase inhibitors
12/17/2003EP1370256A1 Novel inhibitors of formation of advanced glycation endproducts (ages)
12/17/2003EP1370255A2 Cdc25 phosphatase inhibitors
12/17/2003EP1370250A2 Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
12/17/2003EP1370239A1 New composition
12/17/2003EP1370233A2 Filtering composition containing a 1,3,5-triazine derivative, a dibenzoylmethane derivative, and a 4,4-diarylbutadiene compound
12/17/2003EP1370211A2 Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
12/17/2003EP1370148A1 Anticholesterolemic edible oil
12/17/2003EP1246825B1 Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof
12/17/2003EP1226131B1 Isoxazolecarboxamide derivatives
12/17/2003EP1218380B1 Bicyclic imidazo-3-yl-amine derivatives which are substituted on the sixth ring
12/17/2003EP1206467B1 N-heterocyclic derivatives as nos inhibitors
12/17/2003EP1189889B1 Compositions and methods for inhibiting cell death
12/17/2003EP1163024B1 Delivery of macromolecules into cells
12/17/2003EP1142900B1 Siastatin b derivatives having glycosidase inhibitory activities and process for producing the same
12/17/2003EP1115414B1 Inhibition of erythrocyte sickling by n-l-alpha-aspartyl-l-phenylalanine 1-methyl ester
12/17/2003EP1112065B1 Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose deivative
12/17/2003EP1109799B1 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors
12/17/2003EP1102781B1 New cofactors for methyltransferases
12/17/2003EP1100775B1 2,5-substituted benzolsulfonylureas and thioureas, methods for the production thereof, use thereof and pharmaceutical preparations containing the same
12/17/2003EP1098878B1 Bispiperidines as antithrombotic agents
12/17/2003EP1082302B1 A vla-4 inhibitor: omepupa-v
12/17/2003EP1066043B1 Materials for the treatment of conditions involving mast cells, basophils and eosinophils
12/17/2003EP1051392B1 Adamantanecarboximidamide derivatives and their use as nmda antagonists
12/17/2003EP1023296B1 3-substituted pyrido 3',4':4,5] thieno 2,3-d] pyrimidine derivatives, and production and use of the same
12/17/2003EP1001752B1 Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
12/17/2003EP1000047B1 1-(n-phenylaminoalkyl)-piperazine derivatives substituted at position 2 of the phenyl ring
12/17/2003EP0984981B1 Anti-inflammatory tyrosine derivatives
12/17/2003EP0980241B1 Gelatine encapsulated solution dosage forms of sertraline
12/17/2003EP0954580B1 Human sdf-5 protein and compositions
12/17/2003EP0937075B1 New Imidazo- and Oxazolopyridines as Phosphodiesterase Inhibitors.
12/17/2003EP0641218B1 Use of angiotensin antagonist (at1) for reducing post myocardial infarct mobidity and mortality
12/17/2003EP0571387B1 A non-mitogenic competitive hgf antagonist
12/17/2003EP0552142B2 T cell receptor peptides as therapeutics for autoimmune and malignant disease
12/17/2003CN1462276A Peptide-based compounds
12/17/2003CN1462273A Bicyclic heteroaromatic compounds
12/17/2003CN1462270A Imidazole derivatives or their salts
12/17/2003CN1462269A Fused azepine drivatives and their use as antidiuretic agents
12/17/2003CN1462268A Substituted cinnamic acid guanidides, method for the production thereof, their use as medicament, and medicine containing these compounds
1 ... 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 ... 1564